3-DIMETHOXYTHIOPHOSPHORYLAMIDO-2-(2',3',4'-TRI-O-ACETYL-BETA-D-XYLOPYRANOSYL-1'-IMINO)THIAZOLIDINE-4-ONE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	MXVVCHWUWKVTCN-WWBGHNHMSA-N
Smiles	COP(=S)(NN1C(=O)CS/C/1=N/[C@@H]2OC[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@H]2OC(=O)C)OC
InChI	InChI=1S/C16H24N3O10PS2/c1-8(20)27-11-6-26-15(14(29-10(3)22)13(11)28-9(2)21)17-16-19(12(23)7-32-16)18-30(31,24-4)25-5/h11,13-15H,6-7H2,1-5H3,(H,18,31)/b17-16+/t11-,13+,14-,15-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H24N3O10PS2
Molecular Weight	513.48
AlogP	-0.11
Hydrogen Bond Acceptor	13.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	11.0
Polar Surface Area	218.49
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	32.0

Assay Description	Organism	Bioactivity
Growth inhibition of Botryosphaeria berengeriana at 50 ppm relative to control	Botryosphaeria berengeriana	40.0 %
Growth inhibition of Phomopsis asparagi at 50 ppm relative to control	Phomopsis asparagi	40.0 %
Herbicidal activity against Digitaria sanguinalis (hairy crabgrass) assessed as growth inhibition at 1.5 kg/ha relative to control	Digitaria sanguinalis	None
Herbicidal activity against Amaranthus retroflexus assessed as growth inhibition at 1.5 kg/ha relative to control	Amaranthus retroflexus	None
Herbicidal activity against Echinochloa crus-galli (barnyard grass) assessed as growth inhibition at 1.5 kg/ha relative to control	Echinochloa crus-galli	None
Herbicidal activity against Brassica rapa subsp. oleifera assessed as growth inhibition at 1.5 kg/ha relative to control	Brassica rapa subsp. oleifera	None

Cross References

Resources	Reference
ChEMBL	CHEMBL2270677
PubChem	44185169

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).